Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions.
about
Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regionsHerpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivityThe characterization of equine herpes virus-1-infected cell polypeptides recognized by equine lymphocytesRandom linker-insertion mutagenesis to identify functional domains of herpes simplex virus type 1 glycoprotein BDisulfide bond structure of glycoprotein D of herpes simplex virus types 1 and 2Identification of a novel herpes simplex virus type 1-induced glycoprotein which complexes with gE and binds immunoglobulin.Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEMHveA (herpesvirus entry mediator A), a coreceptor for herpes simplex virus entry, also participates in virus-induced cell fusion.Oligomerization of herpes simplex virus glycoprotein B.Soluble glycoprotein D blocks herpes simplex virus type 1 infection of rat eyes.Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface.Anti-glycoprotein g antibodies of herpes simplex virus 2 contribute to complete protection after vaccination in mice and induce antibody-dependent cellular cytotoxicity and complement-mediated cytolysisStructure-function analysis of herpes simplex virus type 1 gD and gH-gL: clues from gDgH chimerasDevelopment of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in miceHerpes simplex virus glycoproteins gB and gD function in a redundant fashion to promote secondary envelopmentGeneration of neutralizing aptamers against herpes simplex virus type 2: potential components of multivalent microbicides.Glycoprotein B of herpes simplex virus 2 has more than one intracellular conformation and is altered by low pH.Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides.Characterization and sequence analyses of antibody-selected antigenic variants of herpes simplex virus show a conformationally complex epitope on glycoprotein H.Genetic analysis of type-specific antigenic determinants of herpes simplex virus glycoprotein C.Herpes simplex virus glycoprotein D mediates interference with herpes simplex virus infectionIdentification of C3b-binding regions on herpes simplex virus type 2 glycoprotein CIdentification of a site on herpes simplex virus type 1 glycoprotein D that is essential for infectivityEntry of herpes simplex virus 1 in BJ cells that constitutively express viral glycoprotein D is by endocytosis and results in degradation of the virusNeutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetrationA herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells.Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetrationAntigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutantsSpecificities of monoclonal and polyclonal antibodies that inhibit adsorption of herpes simplex virus to cells and lack of inhibition by potent neutralizing antibodies.Amino-terminal sequence, synthesis, and membrane insertion of glycoprotein B of herpes simplex virus type 1.Cells expressing herpes simplex virus glycoprotein gC but not gB, gD, or gE are recognized by murine virus-specific cytotoxic T lymphocytes.Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetrationEvaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cellsExploiting herpes simplex virus entry for novel therapeutics.Herpesvirus gB-induced fusion between the virion envelope and outer nuclear membrane during virus egress is regulated by the viral US3 kinase.High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.Anti-idiotypic antibodies mimicking glycoprotein D of herpes simplex virus identify a cellular protein required for virus spread from cell to cell and virus-induced polykaryocytosis.The fusion loops and membrane proximal region of Epstein-Barr virus glycoprotein B (gB) can function in the context of herpes simplex virus 1 gB when substituted individually but not in combination.Residues within the C-terminal arm of the herpes simplex virus 1 glycoprotein B ectodomain contribute to its refolding during the fusion step of virus entry.
P2860
Q24672176-AEC1DE8C-2145-40EE-8F99-9286397F5D63Q24681646-BE014BD0-1904-4A71-BAD0-BAAA18672565Q27473177-AFA1E27E-173E-4A4C-96F6-B4B4F7739E60Q27480974-D16257B4-CDBE-4399-BA86-9D5FDA08265FQ27486188-5F4CED58-C5ED-449B-8620-E4D5D476F86AQ33720617-BC9B6A8F-DD84-40E2-8A5E-9B71158AC047Q33782593-423BD02A-700B-451C-86D0-CCA537AF4348Q33785620-E9068FFE-6A6D-48F4-9DB6-5760CC12F063Q33929693-0B00C3FE-985F-442C-9ABB-82EF377A00F4Q33934324-A08065B7-0BB0-4919-8CEB-C070563E005EQ34335593-0A5FFAA1-7603-410E-BA64-D51416295DCDQ34580831-CCC15C4D-08A5-4CDB-A1B9-5AC1B7A62E2DQ35020198-69834112-05DA-4FC4-AE38-105C7694F96BQ35076638-CDC06511-D190-423F-85D5-F24434710006Q35076641-EAFFF21A-14E4-4A42-A3D6-283F272C5340Q35199134-0B052F6C-2B10-4298-920E-B1473E2EEDB9Q36086658-B323A0F7-45D1-4D5A-96E1-CB5E8BF95480Q36155337-FB41581B-EDF5-40B7-8CD9-AA491394A635Q36681639-576BEB52-B928-49BD-AD42-44CA48F75136Q36688739-9A303C3B-7D77-4526-ADD4-456F0EF3D9AEQ36700361-D2FCC12A-F345-4527-A469-A7F2913C2234Q36780794-32F4DF25-5BA6-45F7-94B5-1122E49272F8Q36804841-BC028633-A7F2-4526-989B-15755A962903Q36811826-039128BB-2CCF-4A32-BBED-BC39D9970A26Q36825917-2397FFC1-44F3-442A-A75E-433A870D91E9Q36829924-9CA1659E-CDEC-4473-A8D1-2698D249A6B6Q36866557-3A607F04-0412-4679-B9B5-E6CD9104695BQ36868421-D7EB365C-9978-4993-8570-1FBF227FC3A0Q36872389-78A3FCA1-380D-4A87-BA0E-4BBE42953264Q36903438-34DCADAC-B58C-4816-B3AF-7DC59EC76E97Q36906662-32AB5AEE-D247-46AB-A967-73DC61D4F746Q36916007-8DF8F3CB-A201-4955-999D-001C416D8538Q36919500-182D326C-DF43-4BC2-A66F-4EDB908AC49EQ36920514-BFEF9CBE-44AD-4557-BE82-465621FA8C2BQ37030702-859C696C-E328-42C1-A8E0-733768DA9687Q37127886-A5158BBC-1734-4FCA-8562-947947C2E44EQ37160338-E3EB55E4-1607-4090-BB15-983DA7D8D7C6Q37702872-1E9B4DB4-6C32-4E04-A906-1A727F807445Q39254906-62FBEDD4-B815-48E0-80E0-F56808E92F14Q39366614-18F4081A-ACC8-4AE8-A4F3-7FFCAA66D44C
P2860
Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Potent neutralizing activity a ...... ing to herpes simplex virions.
@en
type
label
Potent neutralizing activity a ...... ing to herpes simplex virions.
@en
prefLabel
Potent neutralizing activity a ...... ing to herpes simplex virions.
@en
P2093
P2860
P1433
P1476
Potent neutralizing activity a ...... ing to herpes simplex virions.
@en
P2093
P2860
P304
P407
P577
1985-08-01T00:00:00Z